Table 1.
Clinicopathological characteristics in all patients enrolled in this study.
| Characteristics | N (%)/Value |
|---|---|
| Age, median (range), years | 63 (51–79) |
| Gender | |
| Female | 6 (46.2%) |
| Male | 7 (53.8%) |
| BMI, median (range), kg/m2 | 23.84 (14.92–28.95) |
| Hypertensive | 7 (53.8%) |
| Diabetic | 5 (38.5%) |
| Tumor type | |
| Cholangiocarcinoma Gallbladder carcinoma |
6 (46.2%) 7 (53.8%) |
| Tumor location | |
| Gallbladder Hepatic hilar Intrahepatic bile duct Distal bile duct |
7 (53.8%) 3 (23.1%) 1 (7.7%) 2 (15.4%) |
| Tumor differentiation | |
| Poorly differentiated Moderately poorly differentiated Moderately differentiated |
6 (54.5%) 1 (9.1%) 4 (36.4%)) |
| Bile collection method | |
| PTCD Intraoperatively |
2 (15.4%) 11 (84.6%) |
| AJCC Stage | |
| I~II III~IV Tumor, median (range), cm Lymph node invasion |
5 (38.5%) 8 (61.5%) 3 (2~6) 7 (63.6%) |
| ALB, median (range), g/L | 39 (29.1–46.8) |
| TB, median (range), μmol/L | 72.2 (8.3–421.6) |
| AFP, median (range), μg/L | 1.5 (1.3–4.5) |
| CEA, median (range), ng/ml | 11.0 (0.6–11.6) |
| CA19-9, median (range), U/ml | 29.2 (1.2–1911.3) |
BMI, body mass index; PTCD, percutaneous transhepatic cholangial drainage; ALB, albumin; TB, total bilirubin; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 199.